Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with ...

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...

Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the commercial launch of its ...

“We are deeply committed to providing our Omnipod customers with the highest level of service and are confident our high-quality team has the skills and experience to assume direct distribution and ...

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ...

Insulet Corp. PODD recently announced the commercial launch of its Omnipod 5 Automated Insulin Delivery (“AID”) System for individuals aged two years and older with type 1 diabetes (T1D) in the United ...